Type 2 Diabetes Clinical Trial
Official title:
Effects of Fat Metabolites on Gut Hormone Secretion After Gastric Bypass Surgery
To investigate the effects of different fat metabolites on gut hormone secretion in gastric bypass operated subjects and BMI-matched controls.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | December 2018 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Gastric bypass operated patients: Inclusion Criteria: - Uncomplicated gastric bypass surgery performed minimum 12 months prior to study Exclusion Criteria: - Type 1 or 2 diabetes mellitus prior to or after gastric bypass surgery - Pregnancy or breastfeeding - Haemoglobin levels below 6,5 mM - Gall bladder removal Healthy control subjects: Exclusion Criteria: - Bariatric surgery or complicated upper abdominal surgery - Gall bladder removal - Pregnancy or breastfeeding - Haemoglobin levels below 6,5 mM - Co-morbidities or medicine significantly affecting glucose metabolism or appetite regulation |
Country | Name | City | State |
---|---|---|---|
Denmark | Dept. of Endocrinology | Hvidovre |
Lead Sponsor | Collaborator |
---|---|
Hvidovre University Hospital | University of Copenhagen |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Within group difference in glucagon-like peptide-1 (GLP-1) secretion (evaluated by AUC above basal). | Comparison of the GLP-1 responses (evaluated by AUC above basal) induced by the different oils. | 0-240 min following fat ingestion. | |
Primary | Within group difference in Gastric Inhibitory Peptide (GIP) secretion (evaluated by AUC above basal). | Comparison of the GIP responses (evaluated by AUC above basal) induced by the different oils. | 0-240 min following fat ingestion. | |
Primary | Within group difference in cholecystokinin (CCK) secretion (evaluated by AUC above basal). | Comparison of the CCK responses (evaluated by AUC above basal) induced by the different oils. | 0-240 min following fat ingestion. | |
Secondary | Between group comparison of GLP-1 secretion (evaluated by AUC above basal). | GLP-1 secretion (evaluated by AUC above basal) in gastric bypass operated patients compared to BMI-matched control subjects for each of the oils. | 0-240 min following fat ingestion. | |
Secondary | Between group comparison of GIP secretion (evaluated by AUC above basal). | GIP secretion (evaluated by AUC above basal) in gastric bypass operated patients compared to BMI-matched control subjects for each of the oils. | 0-240 min following fat ingestion. | |
Secondary | Between group comparison of CCK secretion (evaluated by AUC above basal). | GIP secretion (evaluated by AUC above basal) in gastric bypass operated patients compared to BMI-matched control subjects for each of the oils. | 0-240 min following fat ingestion. | |
Secondary | Responses (evaluated by AUC above basal) of insulin within and between groups. | 0-240 min following fat ingestion. | ||
Secondary | Responses (evaluated by AUC above basal) of C-peptide within and between groups. | 0-240 min following fat ingestion. | ||
Secondary | Responses (evaluated by AUC above basal) of peptide YY (PYY) within and between groups. | 0-240 min following fat ingestion. | ||
Secondary | Responses (evaluated by AUC above basal) of oxyntomodulin within and between groups. | 0-240 min following fat ingestion. | ||
Secondary | Responses (evaluated by AUC above basal) of glucagon within and between groups. | 0-240 min following fat ingestion. | ||
Secondary | Responses (evaluated by AUC above basal) of bile acids within and between groups. | 0-240 min following fat ingestion. | ||
Secondary | Responses (evaluated by AUC above basal) of fibroblast growth factor 19 (FGF-19) within and between groups. | 0-240 min following fat ingestion. | ||
Secondary | Responses (evaluated by AUC above basal) of lipid metabolites (triglyceride, cholesterol, fatty acids) within and between groups. | 0-240 min following fat ingestion. | ||
Secondary | Responses (evaluated by AUC above basal) of neurotensin within and between groups. | 0-240 min following fat ingestion. | ||
Secondary | Responses (evaluated by AUC above basal) of glucose within and between groups. | 0-240 min following fat ingestion. | ||
Secondary | Between group comparison of differences in GLP-1 secretion (evaluated by AUC above basal). | Differences in GLP-1 secretion (evaluated by AUC above basal) induced by the different oils in gastric bypass operated patients compared with differences in BMI-matched control subjects. | 0-240 min following fat ingestion. | |
Secondary | Between group comparison of differences in GIP secretion (evaluated by AUC above basal). | Differences in GIP secretion (evaluated by AUC above basal) induced by the different oils in gastric bypass operated patients compared with differences in BMI-matched control subjects. | 0-240 min following fat ingestion. | |
Secondary | Between group comparison of differences in CCK secretion (evaluated by AUC above basal). | Differences in CCK secretion (evaluated by AUC above basal) induced by the different oils in gastric bypass operated patients compared with differences in BMI-matched control subjects. | 0-240 min following fat ingestion. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |